Five GLP-1RAs are available in Australia (dulaglutide, exenatide BD, exenatide QW, liraglutide, and lixisenatide), one is undergoing regulatory approval (semaglutide), and three are currently available under the governments reimbursement scheme (dulaglutide, exenatide BD, and exenatide QW)
doi: 10.2147/DMSO.S182406 150 TallmanDLTaylorCG
Several dose escalation arms were studied, with doses ranging from 1 mg up to 12 mg once weekly
In the long term, the benefits of treating obesity and preventing other diseases should outweigh the costs of treating diseases resulting from obesity
The semaglutide segment dominated the market with a major share of 46% in 2025 because of its robust clinical efficacy in glycemic control and weight loss, which is backed by a wealth of empirical data